Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.37 |
| ▸ | CDK2 | P24941 | 3/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | SCN1A | P35498 | 3/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.35 |
| ▸ | SCN8A | Q9UQD0 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5555518 | 0.83 | HCAR3 (0.42) | KDRCCNA2CDK2CCNA1SMN1; SMN2 | |
| SCHEMBL26698946 | 0.76 | — | — | |
| SCHEMBL23415410 | 0.76 | LPAR1 (0.42) | KDRCCNA2CDK2CCNA1SMN1; SMN2 | |
| SCHEMBL28081381 | 0.75 | KDR (0.39) | KDRCCNA2CDK2CCNA1SMN1; SMN2 | |
| SCHEMBL2054005 | 0.74 | MAPKAPK2 (0.55) | CYP3A4CYP2D6CYP2C9MAPKAPK2PIK3CD | |
| SCHEMBL7511795 | 0.74 | CHRNB2 (0.42) | KDRLPAR1MKNK1MAPKAPK2PIK3CD | |
| SCHEMBL30593394 | 0.74 | LPAR1 (0.41) | KDRCCNA2CDK2CCNA1SMN1; SMN2 | |
| SCHEMBL1160955 | 0.74 | MAPKAPK2 (0.55) | CYP3A4CYP2D6CYP2C9MAPKAPK2PIK3CD | |
| SCHEMBL7429834 | 0.74 | CHRNB2 (0.42) | KDRLPAR1MKNK1MAPKAPK2PIK3CD | |
| SCHEMBL20025127 | 0.73 | FDPS (0.50) | SMN1; SMN2CYP2C19HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50030-E1 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-10597387-B2 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20180186780-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186780-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | IRAK1, IRAK4, IRAK2 | KDR 2428/4885CCNA2 1590/4885CDK2 814/4885 |
| US-10597387-B2 | Methods to treat lymphoplasmacytic lymphoma | IRAK1, IRAK4, IRAK2 | KDR 2428/4885CCNA2 1590/4885CDK2 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.